Business Context and Reporting Period
Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: NAI operates primarily in private label contract manufacturing for nutritional supplements and health care products. The company also maintains a branded products segment, primarily the "Pathway to Healing" line. During the period, NAI completed the sale of its legacy Real Health Laboratories (RHL) business, which is now reported as discontinued operations.
Key Financial Metrics
| Metric | Q1 2010 (Ended Sep 30, 2009) | Q1 2009 (Ended Sep 30, 2008) |
|---|---|---|
| Net Sales | $16,961,000 | $19,526,000 |
| Gross Profit | $3,155,000 (18.6% margin) | $2,400,000 (12.3% margin) |
| Operating Income (Continuing Ops) | $1,407,000 | $(218,000) Loss |
| Net Income (Total) | $1,341,000 | $(1,397,000) Loss |
| Net Income Per Share (Diluted) | $0.19 | $(0.20) |
| Cash and Cash Equivalents | $4,483,000 | $3,066,000 |
| Total Debt (Outstanding) | $964,000 | $1,264,000 (Est. based on prior balance) |
| Operating Cash Flow | $1,318,000 | $(640,000) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 13.1% year-over-year. Private label contract manufacturing sales fell 12.6% due to lower volumes from a major customer (NSA International) and the loss of a smaller customer. Branded product sales declined 25.0% due to the softening of the "Pathway to Healing" line following the cessation of Dr. Cherry's television program.
- Profitability Improvement: Despite lower sales, the company turned an operating loss of $218,000 in the prior year into an operating income of $1,407,000. This was driven by a 6.3 percentage point increase in gross margin (to 18.6%) and a 33.2% reduction in selling, general, and administrative (SG&A) expenses due to cost reduction programs and the sale of RHL assets.
- Discontinued Operations: The legacy RHL business was sold for $500,000 in cash (plus potential earn-out). The period included a $6,000 loss on the sale but generated $95,000 in net income from discontinued operations, compared to a $1,048,000 loss in the prior year.
- Foreign Exchange: Other income improved significantly due to favorable foreign currency fluctuations (strengthening Euro), contributing $23,000 in gains compared to a $299,000 loss in the prior year.
Guidance, Outlook, and Risks
- Outlook: Management expects net sales in the second quarter of fiscal 2010 to be relatively consistent with the prior year period. However, net operating income is expected to be positive but at a reduced level compared to Q1 2010 due to anticipated product sales mix and working capital initiatives.
- Strategic Initiatives: The company plans to re-launch the "Pathway to Healing" product line in late fiscal 2010 with new formulations and increased marketing. They intend to continue leveraging their certified facilities to attract new private label customers.
- Customer Concentration Risk: Revenue concentration increased, with the two largest customers accounting for 84% of total net sales from continuing operations (up from 78% in the prior year). The loss of either customer could have a material adverse impact.
- Liquidity: The company has $4.5 million in cash and cash equivalents and $4.6 million available under its working capital line of credit. Management believes these resources are sufficient to fund operations for at least the next 12 months.
- Tax Matters: The company recorded a valuation allowance against deferred tax assets but released a portion during the quarter, offsetting federal tax expense. State tax expense was incurred due to the suspension of California net operating loss carryforwards.
Investor Verification Checklist
- Customer Dependency: Verify the stability of relationships with the top two customers, which represent 84% of revenue.
- Discontinued Operations: Confirm the status of the $500,000 conditional earn-out from the RHL sale and any potential indemnity liabilities capped at the purchase price.
- Branded Product Recovery: Monitor the success of the planned late fiscal 2010 re-launch of the "Pathway to Healing" line to reverse the 25% sales decline.
- Debt Covenants: Review compliance with the $8.5 million credit facility covenants, particularly regarding the $7.5 million working capital line secured by receivables and inventory.
- Inventory Levels: Assess the $10.9 million inventory balance (up from $9.3 million) in the context of declining sales to ensure no obsolescence risks.